Eiger BioPharmaceuticals, Inc.
EIGRQOTCHealthcare
$8.50
+$0.50(+6.25%)
Market Cap$12586800
P/E Ratio—
52W High$16.0
52W Low$1.1
Eiger BioPharmaceuticals, Inc. (EIGRQ) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EIGRQ · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: Apr 8, 2024EPS Actual
-$49.39
Est. -$7.50 · -558.5%
Revenue
—
Est. $0.01B
Fiscal Period
Q2 FY2024
FY ends December
Report Date
Apr 8, 2024
After Market Close
▼ Miss EPS
EIGRQ reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2025 | Apr 7, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 7, 2024 | — | — | — | — | $0.01B | — |
| ◌ Q4 FY2024 | Oct 2, 2024 | -$3.30 | — | — | — | $0.01B | — |
| ▼ Q2 FY2024 | Apr 8, 2024 | -$7.50 | -$49.39 | -558.5% | — | $0.01B | — |
| ▼ Q1 FY2024 | Mar 14, 2024 | -$7.50 | -$49.39 | -558.5% | $0.00B | — | — |
| ▼ Q4 FY2023 | Dec 28, 2023 | -$9.71 | -$12.30 | -26.7% | $0.00B | $0.00B | -20.6% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -$11.70 | -$14.02 | -19.8% | $0.00B | $0.00B | +1.6% |
| ▼ Q1 FY2023 | Mar 31, 2023 | -$13.59 | -$15.48 | -14.0% | $0.00B | $0.00B | -1.2% |
Q2 FY2025
Apr 7, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 7, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Oct 2, 2024
EPS Actual
—
EPS Est.
-$3.30
EPS Surpr.
—
Revenue
—
Q2 FY2024
Apr 8, 2024Miss
EPS Actual
-$49.39
EPS Est.
-$7.50
EPS Surpr.
-558.5%
Revenue
—
Q1 FY2024
Mar 14, 2024Miss
EPS Actual
-$49.39
EPS Est.
-$7.50
EPS Surpr.
-558.5%
Revenue
$0.00B
Q4 FY2023
Dec 28, 2023Miss
EPS Actual
-$12.30
EPS Est.
-$9.71
EPS Surpr.
-26.7%
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023Miss
EPS Actual
-$14.02
EPS Est.
-$11.70
EPS Surpr.
-19.8%
Revenue
$0.00B
Q1 FY2023
Mar 31, 2023Miss
EPS Actual
-$15.48
EPS Est.
-$13.59
EPS Surpr.
-14.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-2.10 | $-2.10 | $-2.10 | 1 |
| Q3 FY2024 | $-3.00 | $-3.00 | $-3.00 | 1 |
| Q2 FY2024 | $-3.30 | $-3.30 | $-3.30 | 1 |
| Q1 FY2024 | $-4.20 | $-4.20 | $-4.20 | 1 |
| Q4 FY2023 | $-6.30 | $-6.30 | $-6.30 | 1 |
| Q3 FY2023 | $-9.31 | $-9.31 | $-9.31 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | Apr 8, 2024 | -558.5% | $2.30 | $2.11 | -8.26% |
| ▼ Q1 FY2024 | Mar 14, 2024 | -558.5% | $6.00 | $5.33 | -11.17% |
| ▼ Q4 FY2023 | Dec 28, 2023 | -26.7% | $6.72 | $7.98 | +18.75% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -19.8% | $16.50 | $21.12 | +28.00% |
| ▼ Q1 FY2023 | Mar 31, 2023 | -14.0% | $27.00 | $26.91 | -0.33% |
| ▼ Q4 FY2022 | Dec 31, 2022 | -7.6% | $35.40 | $37.20 | +5.08% |
| ▼ Q3 FY2022 | Sep 29, 2022 | -21.9% | $240.30 | $236.10 | -1.75% |
| — Q2 FY2022 | Jun 29, 2022 | — | $177.60 | $187.80 | +5.74% |
Q2 FY2024-8.26%
Report Date
Apr 8, 2024
EPS Beat/Miss
-558.5%
Price Before
$2.30
Price After
$2.11
Q1 FY2024-11.17%
Report Date
Mar 14, 2024
EPS Beat/Miss
-558.5%
Price Before
$6.00
Price After
$5.33
Q4 FY2023+18.75%
Report Date
Dec 28, 2023
EPS Beat/Miss
-26.7%
Price Before
$6.72
Price After
$7.98
Q2 FY2023+28.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
-19.8%
Price Before
$16.50
Price After
$21.12
Q1 FY2023-0.33%
Report Date
Mar 31, 2023
EPS Beat/Miss
-14.0%
Price Before
$27.00
Price After
$26.91
Q4 FY2022+5.08%
Report Date
Dec 31, 2022
EPS Beat/Miss
-7.6%
Price Before
$35.40
Price After
$37.20
Q3 FY2022-1.75%
Report Date
Sep 29, 2022
EPS Beat/Miss
-21.9%
Price Before
$240.30
Price After
$236.10
Q2 FY2022+5.74%
Report Date
Jun 29, 2022
EPS Beat/Miss
—
Price Before
$177.60
Price After
$187.80
Avg Miss Reaction+4.33%
Beat Rate0 / 8 quarters
Largest Move+28.00% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EIGRQ ends December
Eiger BioPharmaceuticals, Inc. (EIGRQ) most recently reported earnings on April 8, 2024 for Q2 FY2024, posting EPS of $-49.39 — missing the analyst consensus of $-7.50 by -558.5%. The next EIGRQ earnings date is expected around September 1, 2026.
Each quarter, investors track EIGRQ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EIGRQ revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EIGRQ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EIGRQ earnings · 5 questionsEiger BioPharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. EIGRQ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EIGRQ historically reports after market close (AMC).
EIGRQ earnings datewhen is EIGRQ earningsEIGRQ next earnings datewhen does EIGRQ report earningsEIGRQ earnings calendar
▸ Source: FMP · Eiger BioPharmaceuticals, Inc. SEC filings · US GAAP · Eiger BioPharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026